Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752730 | 1.00 | KMT2A (0.49) | KMT2AGFERMAPTAKR1C3SMN1; SMN2 | |
| SCHEMBL16769362 | 0.86 | KMT2A (0.52) | KMT2AGFERMAPTAKR1C3SMN1; SMN2 | |
| SCHEMBL17938065 | 0.84 | AKR1C3 (0.59) | KMT2AGFERMAPTAKR1C3SMN1; SMN2 | |
| SCHEMBL16752740 | 0.84 | AKR1C3 (0.59) | KMT2AGFERMAPTAKR1C3SMN1; SMN2 | |
| SCHEMBL25262380 | 0.81 | MAPT (0.66) | KMT2AMAPTAKR1C3SMN1; SMN2L3MBTL1 | |
| SCHEMBL21339818 | 0.76 | NOTUM (0.68) | KMT2AMAPTAKR1C3SMN1; SMN2L3MBTL1 | |
| SCHEMBL20840870 | 0.76 | NOTUM (0.68) | KMT2AMAPTAKR1C3SMN1; SMN2L3MBTL1 | |
| SCHEMBL20840854 | 0.75 | NOTUM (0.54) | KMT2AMAPTAKR1C3SMN1; SMN2L3MBTL1 | |
| SCHEMBL29284129 | 0.75 | TP53 (0.40) | SMN1; SMN2DPP4 | |
| SCHEMBL1700363 | 0.74 | TP53 (0.39) | SMN1; SMN2L3MBTL1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870140-B1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LTD (IN) | 2016-07-27 | — | — | EP | disclosed |
| US-9359367-B2 | Tetrahydroquinazolinone derivatives as PARP inhibitors | LUPIN LIMITED (IN) | 2016-06-07 | — | — | US | disclosed |
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | LUPIN LIMITED (IN) | 2015-06-04 | — | — | US | disclosed |
| EP-2870140-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | Lupin Limited (IN) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014009872-A1 | TETRAHYDROQUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | LUPIN LIMITED (IN) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152118-A1 | Tetrahydroquinazolinone Derivatives as PARP Inhibitors | PARP1, PARP11, PARP3 | KMT2A 113/4885GFER 4021/4885MAPT 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.